Soon-Shiong immuno-oncology startup NantCell rakes in $57M
Another load of cash - and little further insight - is on the books for Patrick Soon-Shiong cancer immunotherapy startup NantCell.
Two of Patrick Soon-Shiong’s NantWorks startups net $250M
Dr. Patrick Soon-Shiong has two more fundraises under his companies' belt: According to an SEC filing, immuno-oncology startup NantCell has raised $100 million and precision medicine startup NantOmics has raised $150 million.
presented by
Price Transparency is the New North in the PBM World
In this episode hear how improving benefit verification, prior authorizations, and patient affordability with smart integrations and real-time eligibility can streamline healthcare workflows.
Soon-Shiong outfit NantCell raises $75M; focus is on cancer immunotherapy
The mysterious company just allocated $75 million to its NantCell division - putting some serious funding behind its precision medicine and cancer immunotherapy efforts.